(FTRE) Fortrea Holdings - Overview
Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 896m | Total Return 8.5% in 12m
Stock: Clinical Trials, Lab Testing, Regulatory Consulting
Total Rating 22
Risk 33
Buy Signal -1.21
| Risk 5d forecast | |
|---|---|
| Volatility | 88.9% |
| Relative Tail Risk | -11.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.50 |
| Alpha | -10.67 |
| Character TTM | |
|---|---|
| Beta | 1.609 |
| Beta Downside | 1.941 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.92% |
| CAGR/Max DD | -0.39 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
volatile
Description: FTRE Fortrea Holdings March 20, 2026
Fortrea Holdings Inc. (FTRE) is a contract research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices. CROs are integral to the drug development process, offering specialized services that pharmaceutical companies often outsource to reduce costs and accelerate timelines.
Fortreas services encompass clinical pharmacology, including early-phase clinical trials and bioanalytical support. They also provide comprehensive clinical development services, covering Phase I through IV studies, regulatory affairs, and pharmacovigilance. This broad range of services highlights the full-spectrum support CROs offer, from initial drug discovery to post-market surveillance.
Additionally, Fortrea offers consulting services, focusing on product development, regulatory guidance, market access, and real-world evidence (RWE) studies. These consulting services help clients navigate complex regulatory landscapes and optimize product commercialization strategies.
To gain further insights into Fortreas operational performance and financial health, consider exploring its detailed analytics on ValueRay.
Headlines to watch out for
- Biopharmaceutical R&D spending directly impacts Fortreas service demand
- Clinical trial pipeline growth fuels Fortreas revenue expansion
- Regulatory changes in drug development affect service requirements
- Competition from other CROs pressures Fortreas market share
- Macroeconomic conditions influence client investment in drug development
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -986.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -3.38 > 1.0 |
| NWC/Revenue: -0.59% < 20% (prev -0.05%; Δ -0.54% < -1%) |
| CFO/TA 0.04 > 3% & CFO 113.5m > Net Income -986.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (91.2m) vs 12m ago 1.33% < -2% |
| Gross Margin: 16.35% > 18% (prev 0.20%; Δ 1.62k% > 0.5%) |
| Asset Turnover: 86.53% > 50% (prev 75.34%; Δ 11.19% > 0%) |
| Interest Coverage Ratio: -9.77 > 6 (EBITDA TTM -813.7m / Interest Expense TTM 91.3m) |
Altman Z'' -4.36
| A: -0.01 (Total Current Assets 897.2m - Total Current Liabilities 913.3m) / Total Assets 2.72b |
| B: -0.51 (Retained Earnings -1.38b / Total Assets 2.72b) |
| C: -0.28 (EBIT TTM -891.7m / Avg Total Assets 3.15b) |
| D: -0.72 (Book Value of Equity -1.55b / Total Liabilities 2.15b) |
| Altman-Z'' Score: -4.36 = D |
Beneish M -3.44
| DSRI: 0.84 (Receivables 589.7m/694.0m, Revenue 2.72b/2.70b) |
| GMI: 1.21 (GM 16.35% / 19.81%) |
| AQI: 0.89 (AQ_t 0.61 / AQ_t-1 0.69) |
| SGI: 1.01 (Revenue 2.72b / 2.70b) |
| TATA: -0.40 (NI -986.2m - CFO 113.5m) / TA 2.72b) |
| Beneish M-Score: -3.44 (Cap -4..+1) = AA |
What is the price of FTRE shares?
As of March 29, 2026, the stock is trading at USD 9.07 with a total of 776,740 shares traded.
Over the past week, the price has changed by -4.83%, over one month by -15.39%, over three months by -47.42% and over the past year by +8.49%.
Over the past week, the price has changed by -4.83%, over one month by -15.39%, over three months by -47.42% and over the past year by +8.49%.
Is FTRE a buy, sell or hold?
Fortrea Holdings has received a consensus analysts rating of 3.00.
Therefor, it is recommend to hold FTRE.
- StrongBuy: 0
- Buy: 1
- Hold: 10
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the FTRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.4 | 58.2% |
| Analysts Target Price | 14.4 | 58.2% |
FTRE Fundamental Data Overview March 26, 2026
P/E Forward = 5.5402
P/S = 0.3289
P/B = 1.5813
P/EG = 0.3442
Revenue TTM = 2.72b USD
EBIT TTM = -891.7m USD
EBITDA TTM = -813.7m USD
Long Term Debt = 1.05b USD (from longTermDebt, last quarter)
Short Term Debt = 14.0m USD (from shortTermDebt, last quarter)
Debt = 68.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -106.6m USD (from netDebt column, last quarter)
Enterprise Value = 789.1m USD (895.7m + Debt 68.0m - CCE 174.6m)
Interest Coverage Ratio = -9.77 (Ebit TTM -891.7m / Interest Expense TTM 91.3m)
EV/FCF = 8.94x (Enterprise Value 789.1m / FCF TTM 88.3m)
FCF Yield = 11.19% (FCF TTM 88.3m / Enterprise Value 789.1m)
FCF Margin = 3.24% (FCF TTM 88.3m / Revenue TTM 2.72b)
Net Margin = -36.21% (Net Income TTM -986.2m / Revenue TTM 2.72b)
Gross Margin = 16.35% ((Revenue TTM 2.72b - Cost of Revenue TTM 2.28b) / Revenue TTM)
Gross Margin QoQ = 16.93% (prev 14.70%)
Tobins Q-Ratio = 0.29 (Enterprise Value 789.1m / Total Assets 2.72b)
Interest Expense / Debt = 34.12% (Interest Expense 23.2m / Debt 68.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -704.4m (EBIT -891.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.98 (Total Current Assets 897.2m / Total Current Liabilities 913.3m)
Debt / Equity = 0.12 (Debt 68.0m / totalStockholderEquity, last quarter 563.5m)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -106.6m / EBITDA -813.7m)
Debt / FCF = -1.21 (Net Debt -106.6m / FCF TTM 88.3m)
Total Stockholder Equity = 648.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.33% (Net Income -986.2m / Total Assets 2.72b)
RoE = -152.2% (Net Income TTM -986.2m / Total Stockholder Equity 648.1m)
RoCE = -52.57% (EBIT -891.7m / Capital Employed (Equity 648.1m + L.T.Debt 1.05b))
RoIC = -39.35% (negative operating profit) (NOPAT -704.4m / Invested Capital 1.79b)
WACC = 12.72% (E(895.7m)/V(963.7m) * Re(11.64%) + D(68.0m)/V(963.7m) * Rd(34.12%) * (1-Tc(0.21)))
Discount Rate = 11.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.91%
[DCF] Terminal Value 67.15% ; FCFF base≈147.9m ; Y1≈177.4m ; Y5≈283.7m
[DCF] Fair Price = 27.45 (EV 2.46b - Net Debt -106.6m = Equity 2.57b / Shares 93.5m; r=12.72% [WACC]; 5y FCF grow 21.29% → 3.0% )
EPS Correlation: -32.09 | EPS CAGR: -44.48% | SUE: -2.94 | # QB: 0
Revenue Correlation: -20.17 | Revenue CAGR: -4.30% | SUE: -0.04 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.18 | Chg7d=+0.000 | Chg30d=-0.022 | Revisions Net=+0 | Analysts=9
EPS current Year (2026-12-31): EPS=0.72 | Chg7d=+0.000 | Chg30d=-0.059 | Revisions Net=-4 | Growth EPS=+68.1% | Growth Revenue=-4.4%
EPS next Year (2027-12-31): EPS=0.96 | Chg7d=+0.000 | Chg30d=-0.128 | Revisions Net=-5 | Growth EPS=+33.3% | Growth Revenue=+3.1%
[Analyst] Revisions Ratio: +0.00 (4 Up / 4 Down within 30d for Next Quarter)
P/S = 0.3289
P/B = 1.5813
P/EG = 0.3442
Revenue TTM = 2.72b USD
EBIT TTM = -891.7m USD
EBITDA TTM = -813.7m USD
Long Term Debt = 1.05b USD (from longTermDebt, last quarter)
Short Term Debt = 14.0m USD (from shortTermDebt, last quarter)
Debt = 68.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -106.6m USD (from netDebt column, last quarter)
Enterprise Value = 789.1m USD (895.7m + Debt 68.0m - CCE 174.6m)
Interest Coverage Ratio = -9.77 (Ebit TTM -891.7m / Interest Expense TTM 91.3m)
EV/FCF = 8.94x (Enterprise Value 789.1m / FCF TTM 88.3m)
FCF Yield = 11.19% (FCF TTM 88.3m / Enterprise Value 789.1m)
FCF Margin = 3.24% (FCF TTM 88.3m / Revenue TTM 2.72b)
Net Margin = -36.21% (Net Income TTM -986.2m / Revenue TTM 2.72b)
Gross Margin = 16.35% ((Revenue TTM 2.72b - Cost of Revenue TTM 2.28b) / Revenue TTM)
Gross Margin QoQ = 16.93% (prev 14.70%)
Tobins Q-Ratio = 0.29 (Enterprise Value 789.1m / Total Assets 2.72b)
Interest Expense / Debt = 34.12% (Interest Expense 23.2m / Debt 68.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -704.4m (EBIT -891.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.98 (Total Current Assets 897.2m / Total Current Liabilities 913.3m)
Debt / Equity = 0.12 (Debt 68.0m / totalStockholderEquity, last quarter 563.5m)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -106.6m / EBITDA -813.7m)
Debt / FCF = -1.21 (Net Debt -106.6m / FCF TTM 88.3m)
Total Stockholder Equity = 648.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.33% (Net Income -986.2m / Total Assets 2.72b)
RoE = -152.2% (Net Income TTM -986.2m / Total Stockholder Equity 648.1m)
RoCE = -52.57% (EBIT -891.7m / Capital Employed (Equity 648.1m + L.T.Debt 1.05b))
RoIC = -39.35% (negative operating profit) (NOPAT -704.4m / Invested Capital 1.79b)
WACC = 12.72% (E(895.7m)/V(963.7m) * Re(11.64%) + D(68.0m)/V(963.7m) * Rd(34.12%) * (1-Tc(0.21)))
Discount Rate = 11.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.91%
[DCF] Terminal Value 67.15% ; FCFF base≈147.9m ; Y1≈177.4m ; Y5≈283.7m
[DCF] Fair Price = 27.45 (EV 2.46b - Net Debt -106.6m = Equity 2.57b / Shares 93.5m; r=12.72% [WACC]; 5y FCF grow 21.29% → 3.0% )
EPS Correlation: -32.09 | EPS CAGR: -44.48% | SUE: -2.94 | # QB: 0
Revenue Correlation: -20.17 | Revenue CAGR: -4.30% | SUE: -0.04 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.18 | Chg7d=+0.000 | Chg30d=-0.022 | Revisions Net=+0 | Analysts=9
EPS current Year (2026-12-31): EPS=0.72 | Chg7d=+0.000 | Chg30d=-0.059 | Revisions Net=-4 | Growth EPS=+68.1% | Growth Revenue=-4.4%
EPS next Year (2027-12-31): EPS=0.96 | Chg7d=+0.000 | Chg30d=-0.128 | Revisions Net=-5 | Growth EPS=+33.3% | Growth Revenue=+3.1%
[Analyst] Revisions Ratio: +0.00 (4 Up / 4 Down within 30d for Next Quarter)